Substituted isoxazoles for treating cancer

1. A compound having Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is selected from the group consisting of ethyl and cyclopropyl;

R 2a , R 2b , R 3a , and R 3b are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, alkoxy, alkyoxyalkyl, aralkyl, and —C(═O)R 6c ; or

R 2a and R 2b taken together form a C 1-4 bridge; and R 3a and R 3b are independently selected from the group consisting of hydrogen, C 1-4 alkyl, alkoxy, alkyoxyalkyl, aralkyl, and —C(═O)R 6c ; or

R 3a and R 3b taken together a form a C 1-4 bridge; and R 2a and R 2b are independently selected from the group consisting of hydrogen, C 1-4 alkyl, alkoxy, alkyoxyalkyl, aralkyl, and —C(═O)R 6c ; or

R 2a and R 3b taken together form a C 1-4 bridge; and R 2b and R 3a are independently selected from the group consisting of hydrogen, C 1-4 alkyl, alkoxy, alkyoxyalkyl, aralkyl, and —C(═O)R 6c ; or

R 2b and R 3a taken together form a C 1-4 bridge; and R 2a and R 3b are independently selected from the group consisting of hydrogen, C 1-4 alkyl, alkoxy, alkyoxyalkyl, aralkyl, and —C(═O)R 6c ; or

R 4 is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, substituted C 1-6 alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, —C(═O)R 6a , and —S(═O) 2 R 6b ;

R 5 is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, substituted C 1-6 , alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, and (heterocyclo)alkyl;

R 6a is selected from the group consisting of unsubstituted C 1-6 alkyl, substituted C 1-6 alkyl, alkoxy, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylalmino)alkyl, (heterocyclo)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, unsubstituted C 4-14 heterocyclo, substituted C 4-14 heterocyclo, unsubstituted C 5-14 heteroaryl, substituted C 5-14 heteroaryl, unsubstituted C 3-12 cycloalkyl, and substituted C 3-12 cycloalkyl;

R 6b is selected from the group consisting of unsubstituted C 1-6 alkyl, substituted C 1-6 alkyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkyl amino) alkyl, (heterocyclo)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, unsubstituted C 4-14 heterocyclo, substituted C 4-14 heterocyclo, unsubstituted C 5-14 heteroaryl, substituted C 5-14 heteroaryl, unsubstituted C 3-12 cycloalkyl, and substituted C 3-12 cycloalkyl;

R 6c is selected from the group consisting of unsubstituted C 1-6 alkyl, substituted C 1-6 alkyl, amino, alkylamino, dialkylamino, cycloalkylamino, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cyclo alkylamino) alkyl, (heterocyclo)alkyl, (amino)(hydroxy)alkyl, (aralkylamino)alkyl, unsubstituted C 4-14 heterocyclo, substituted C 4-14 heterocyclo, unsubstituted C 5-14 heteroaryl, substituted C 5-14 heteroaryl, unsubstituted C 3-12 cycloalkyl, and substituted C 3-12 cycloalkyl;

R 7 is selected from the group consisting of hydrogen, C 1-6 alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, and alkoxyalkyl;

each substituted C 1-6 alkyl is independently substituted with one, two, or three substituents independently selected from the group consisting of nitro, haloalkoxy, aryloxy, aralkyloxy, alkylthio, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, alkoxycarbonyl, and carboxyalkyl;

each substituted C 4-14 heterocyclo is independently substituted with one, two, three, or four substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, and (heteroaryl)alkyl;

each substituted C 5-14 heteroaryl is independently substituted with one, two, three, or four substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aralkyl aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R 43 )(R 44 ), and —N(H)C(═O)—R 45 ;

each substituted C 3-12 cycloalkyl is independently substituted with one, two, or three substituents independently selected from the group consisting ofhalo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, and (heteroaryl)alkyl;

R 43 is hydrogen or C 1-4 alkyl;

R 44 is alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl, (alkylamino)alkyl, or (dialkylamino)alkyl; and

R 45 is alkyl; unsubstituted C 6-14 aryl; substituted C 6-14 aryl with one, two, three, four, or five substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy; unsubstituted C 5-14 heteroaryl; or substituted C 5-14 heteroaryl with one, two, three, or four substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, and haloalkoxy,

with the proviso that said compound having Formula I is not:

N-(4-aminocyclohexyl)-5-cyclopropyl-N-methylisoxazole-3-carboxamide;

N-((1s,4s)-4-aminocyclohexyl)-5-ethyl-N-(3-(trifluoromethoxy)benzyl)isoxazole-3-carboxamide;

N-(4((3-(difluoromethoxy)benzyl)amino)cyclohexyl)-5-ethyl-N-(3-(trifluoromethoxy) benzyl)isoxazole-3-carboxamide; or

5-ethyl-N-(3-(trifluoromethoxy)benzyl)-N-(4-((4-(trifluoromethoxy)benzyl)amino) cyclohexyl)isoxazole-3-carboxamide.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is cyclopropyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2a ,R 2b , and R 3a are each independently hydrogen.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is —C(═O)R 6a .

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is —S(═O) 2 R 6b .

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is C 1-6 alkyl.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from the group consisting of —CH 2 CH 2 OH, —CH 2 CH 2 NH 2 , CH 2 CH 2 CH 2 OH, and —CH 2 CH 2 CH 2 NH 2 .

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6a is selected from the group consisting of:

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6b is selected from the group consisting of:

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is hydrogen.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from the group consisting of C 1-4 alkyl, hydroxyalkyl, and alkoxyalkyl.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having Formula II, Formula III, Formula IV, Formula V, Formula VI, or Formula VII:

or

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having Formula VIII, Formula IX, Formula X, Formula XI, Formula XII, or Formula XIII:

or

15. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

17. A kit comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt thereof, to a patient having cancer.

18. A method for inhibiting SET and MYND domain proteins in a patient, the method comprising administering to the patient a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

19. The method of claim 18 , wherein the patient has cancer.

20. The method of claim 19 , wherein the cancer is selected from the group consisting of adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentigious melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive natural killer-cell leukemia, acquired immune definciency syndrome-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogeous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, mucosa-associated lymphoid tissue lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, preimary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma periotonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms' tumor.